Age-dependent dopaminergic dysfunction in Nurr1 knockout mice

Experimental Neurology

Volumn 191, Issue 1, 2005, Pages 154-162

  Jiang, Chuantao ^a   Wan, Xinhua ^a   He, Yi ^a   Pan, Tianhong ^a   Jankovic, Joseph ^a   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aging; Dopamine; Motor impairment; Nurr1+ mice; Parkinson disease

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; NUCLEAR RECEPTOR RELATED FACTOR 1;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC ACTIVITY; EMBRYO; FEMALE; GENE EXPRESSION; HETEROZYGOTE; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN FUNCTION; SPECIES COMPARISON; STRIATONIGRAL DEGENERATION; WILD TYPE;

AGING; ANIMALS; DNA-BINDING PROTEINS; DOPAMINE; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TRANSCRIPTION FACTORS;

EID: 10044247254     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.08.035     Document Type: Article

References (36)

1. P.K. Auluck, H.Y.E. Chan, J.Q. Trojanowski, V.M.Y. Lee, and N.M. Bonini Chaperone suppression of α-synuclein toxicity in a drosophila model for Parkinson's disease Science 295 2002 865 868
2. C. Backman, Z.B. You, and T. Perlmann Elevated locomotor activity without altered striatal dopamine contents in Nurr1 heterozygous mice after acute exposure to methamphetamine Behav. Brain Res. 143 2003 95 100
3. M.J. Baptista, C. O'Farrell, C.S. Daya, R. Ahmad, D.W. Miller, J. Hardy, M.J. Farrer, and M.R. Cookson Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines J. Neurochem. 85 2003 957 968
4. R. Betarbet, T.B. Sherer, and G. MacKenzie Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat. Neurosci. 3 2000 1301 1306
5. D.B. Calne, and M.J. Zigmond Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism Arch. Neurol. 48 1991 361 363
6. S.O. Castrillo, J.S. Baffi, M. Oalkivis, D.S. Goldstein, I.J. Kopin, J. Witta, M.A. Magnuson, and V.M. Nikodem Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene Mol. Cell. Neurosci. 11 1998 36 46
7. Y. Chu, K. Kompoliti, E.J. Cochran, E.J. Mufson, and J.H. Kordower Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra J. Comp. Neurol. 450 2002 203 214
8. Y. Chu, W.D. Le, K. Kompoliti, and J.H. Kordower Decreased of Nurr1 expression in remaining nigral dopaminergic neurons of Parkinson's disease Abstr. Ann. Meet. Soc. Neurosci. 78 2003 13
9. T.M. Dawson, and V. Dawson Molecular pathways of neurodegeneration in Parkinson's disease Science 302 2003 819 822
10. J.B. Eells, B.K. Lipska, S.K. Yeung, J.A. Misler, and V.M. Nikodem Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity Behav. Brain Res. 136 2002 267 275
11. J.B. Eells, S.K. Yeung, and V.M. Nikodem Dopamine neurons heterozygous for the Nurr1-Null allele have reduced survival in vitro Neurosci. Res. Commun. 30 2002 173 183
12. J. Fearnley, and A.J. Lees Aging and Parkinson's disease: substantia nigra regional selectivity Brain 114 1991 2283 2301
13. E.K.B.J. Franlin, and G. Paxinos The Mouse Brain in Stereotaxic Coordinates 1996 Academic Press San Diego
14. W.R. Gibb, and A.J. Lees Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease J. Neurol., Neurosurg., Psychiatry 54 1991 388 396
15. Y. Glinka, M. Gassen, and M.B. Youdim Mechanism of 6-hydroxydopamine neurotoxicity J. Neural Transm., Suppl. 50 1997 55 66
16. Y. He, S.Z. Imann, Z. Dong, J. Jankovic, S.F. Ali, S.H. Appel, and W.D. Le Role of nitric oxide in rotenone-induced nigro-striatal injury J. Neurochem. 86 2003 1338 1345
17. E. Hermanson, B. Joseph, and D. Castro Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells Exp. Cell Res. 288 2003 324 334
18. P. Jenner The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease Parkinsonism Relat. Disord. 9 2003 131 137
19. N. Lapointe, M. St-Hilaire, M.G. Martinoli, J. Blanchet, P. Gould, C. Rouillard, and F. Cicchetti Rotenone induces non-specific central nervous system and systemic toxicity FASEB J. 18 2004 717 719
20. S.W. Law, O.M. Conneely, F.J. DeMayo, and B.W. O'Malley Identification of a new brain-specific transcription factor, NURR1 Mol. Endocrinol. 6 1992 2129 2135
21. W.D. Le, and S.H. Appel Mutant genes responsible for Parkinson's disease Curr. Opin. Pharmacol. 4 2004 79 84
22. W.D. Le, J.T. Bostwick, and S.H. Appel Use of 3H-GBR12935 to measure dopaminergic nerve terminal growth into rat striatum Dev. Brain Res. 67 1992 375 377
23. W.D. Le, O.M. Conneely, and L. Zou Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice Exp. Neurol. 159 1999 451 458
24. W.D. Le, O.M. Conneely, and Y. He Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury J. Neurochem. 73 1999 2218 2221
25. C.S. Lee, A. Samii, and V. Sossi In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease Ann. Neurol. 47 2000 493 503
26. M. Orth, and S.J. Tabrizi Models of Parkinson's disease Mov. Disord. 18 2003 729 737
27. B. Pakkenberg, A. Moller, H.J.G. Gundersen, A.M. Dam, and H. Pakkengerg The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method J. Neurol., Neurosurg., Psychiatry 54 1991 30 33
28. G. Rozas, E. Lopez-Martin, and M.J. Guerra The overall rod performance test in the MPTP-treated mouse model of parkinsonism J. Neurosci. Methods 83 1998 165 175
29. O. Saucedo-Cardenas, J.D. Quintana-Hau, W.D. Le, M.P. Smidt, J.J. Cox, F.D. Mayo, J.H. Burbach, and O.M. Conneely Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons Proc. Natl. Acad. Sci. U. S. A. 95 1998 4013 4018
30. S.M. Smits, T. Ponnio, O.M. Conneely, J.P. Burbach, and M.P. Smidt Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons Eur. J. Neurosci. 18 2003 1731 1738
31. J. Tedroff, A. Ekesbo, E. Rydin, B. Langston, and G. Hagberg Regulation of dopaminergic activity in early Parkinson's disease Ann. Neurol. 46 1999 359 365
32. M. Thiruchelvam, A. McCormack, E.K. Richfield, R.B. Baggs, A.W. Tank, D.A. Di Monte, and D.A. Cory-Slechta Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype Eur. J. Neurosci. 18 2003 589 600
33. J.L. Tillerson, W.M. Caudle, M.E. Reveron, and G.W. Miller Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Exp. Neurol. 178 2002 80 90
34. D. Twelves, K.S. Perkins, and C. Counsell Systematic review of incidence studies of Parkinson's disease Mov. Disord. 18 2003 19 31
35. A.L. Whone, R.Y. Moore, P.P. Piccini, and D.J. Brooks Plasticity of the nigropallidal pathway in Parkinson's disease Ann. Neurol. 53 2003 206 213
36. R.H. Zetterstrom, L. Solomin, L. Jansson, B.J. Hoffer, L. Olson, and T. Perlmann Dopamine neuron agenesis in Nurr1-deficient mice Science 276 1997 248 250